Welcome to Bayer US Medical Affairs

This site is intended to provide balanced, evidence-based, scientific information for the education of healthcare professionals licensed to practice in the United States. The information provided is not intended to provide medical advice or to promote or recommend any therapy or course of treatment. Content on the site may contain information, or links to information, about or related to investigational compounds that have not been approved by the U.S. Food and Drug Administration (FDA) and investigational, new uses of FDA-approved Bayer products. Please refer to the full Prescribing Information for approved indications, contraindications, warnings, precautions, and adverse events. If you are not a U.S. healthcare professional, please discuss any questions you have regarding your health or therapies with your healthcare provider.
If you are a U.S. healthcare professional and you understand and accept the purpose and limitations of this site as described above, click “Yes” to enter the Bayer US Medical Affairs website.

Home
Disease Education
Congress Library
Publications
Clinical Trials
Pipeline & Research
Continuing Education
Guidelines & Organizations
Product Information
Connect
Other Therapeutic Areas

Home
Disease Education
Congress Library
Publications
Clinical Trials
Pipeline & Research
Continuing Education
Guidelines & Organizations
Product Information
Connect
Other Therapeutic Areas

Country select
- Country 1
- Country 2

Publications

Home/Publications

We invite you to explore Bayer-supported publications. This library is not intended to serve as a comprehensive repository of all publications. Publications not supported by Bayer are not included. Access to the full text of publications may depend on journal access rights.

To help narrow down your search, choose the relevant tags and click Apply. Selecting multiple tags will narrow your results.

Last updated September 16, 2025.

Colorectal Cancer

Hepatocellular Cancer

Other Solid Tumors

Prostate Cancer

Thyroid Cancer

Types of Enhancements Available

Audio

Infographic

Plain Language Summary

Video

Other

To help narrow down your search, select the relevant filters from the dropdowns and Click Apply

Sort by:

Audience / Type

Biomarker study

Case Study

Genetic Testing

Guidelines

Literature Reviews & Metanalysis

Other

Pharmacology

Phase 1

Phase 2

Phase 3

Phase 4

Phase 5

Post-marketing

Pre-clinical

Primary Manuscript

Qualitative Research

Real World Evidence & Health Economics and Outcomes Research

Review Article

Secondary Manuscript

Study design

Topic

Breast cancer

Colorectal cancer

Drug-drug interactions

Gastric cancer

GIST

Health inequality

Healthcare resource utilization

Hematological malignancies

Hepatocellular cancer

infantile sarcoma

Lung cancer

mCRC

mCRPC

Metastases

mHSPC

neuroendocrine tumors

Other solid tumors

pediatric solid tumors

Preclinical

Prostate cancer

Sarcoma

solid tumors

Thyroid cancer

TRK-fusion cancer

Year

Hold down Ctrl key on keyboard to select multiple years

Total available publications: 339

Filtered results: 48

Imatinib alternating with regorafenib compared to imatinib alone for the first-line treatment of advanced gastrointestinal stromal tumor: The AGITG ALT-GIST intergroup randomized phase II trial: Clinical Studies

Yip D., et al. British Journal of Cancer. 2025;132(10):897-904.

Yip D.; Zalcberg J.; Blay J.-Y.; Eriksson M.; Espinoza D.; Price,

READ

COREGO: drug–drug interaction analysis on the efficacy and safety of regorafenib in patients with a sarcoma: pooled analysis of the data from the REGOSARC and REGOBONE trials

Rethouse F., et al. ESMO Open. 2025;10(6):105117.

Rethouze F.; Risbourg S.; Schiffler C.; Chabaud S.; de Courrèges,

READ

Regorafenib as maintenance therapy after first-line doxorubicin-based chemotherapy in advanced non-adipocytic soft tissue sarcomas patients: a double-blind randomised trial

Penel N., et al. Annals of Oncology. 2025;36(8):944 - 953.

Penel N.; Italiano A.; Wallet J.; Chaigneau L.; Verret B.; ,

READ

Larotrectinib for Newly Diagnosed Infantile Fibrosarcoma and Other Pediatric NTRK Fusion-Positive Solid Tumors (Children's Oncology Group ADVL1823)

Laetsch T.W., et al. Journal of Clinical Oncology. 2025;43(10):1188–1197.

Laetsch T.W.; Voss S.; Ludwig K.; Hall D.; Barkauskas D.A.; Dubo,

READ

Safety and Efficacy of Copanlisib in Combination with Nivolumab: A Phase Ib Study in Patients with Advanced Solid Tumors

Carneiro B.A., et al. Cancer Research Communications. 2025;5(3):444–457.

Carneiro B.A.; Jotte R.M.; Gabrail N.Y.; Wentzel K.; Huang F.; C,

READ

Efficacy and Safety of Larotrectinib in TRK Fusion-Positive Primary Central Nervous System Tumors

Doz F, et al. Neuro Oncol. 2022;24(6):997-1007.

Doz F,

READ

Phase I dose escalation study of sorafenib plus S-1 for advanced solid tumors

Tsai H J, et al. Sci Rep.2021;11(1):4834.

Tsai H J,

READ

Phase 1 Study of Sorafenib and Irinotecan in Pediatric Patients with Relapsed or Refractory Solid Tumors

Meany HJ, et al. Pediatr Blood Cancer. 2021;e29282.

Meany HJ,

READ

Resound Trial: A phase 2 study of regorafenib in patients with thymoma (type B2-B3) and thymic carcinoma previously treated with chemotherapy

Perrino M, et al. Cancer. 2021; Vol 128: Issue 4.

Perrino M,

READ

Phase I dose-escalation and pharmacokinetic study of regorafenib in pediatric patients with recurrent or refractory solid malignancies

Geoerger B, et al. Eur J of cancer. 2021;153:142-152.

Geoerger B,

READ

Current page 1
Page 2
Page 3
Page 4
Page 5
Next page
Last page

You are encouraged to report side effects or quality complaints of products to the FDA by visiting www.fda.gov/medwatch or calling 1-800-FDA-1088. For Bayer products, you can report these directly to Bayer by clicking here.

This site provides access to balanced and evidence-based medical information related to our therapeutic areas of focus and is intended to serve as a medical resource for US HCPs. This may include investigational compounds or investigational new uses of FDA-approved Bayer products. The information provided is not intended to be promotional or provide medical advice. Please refer to the full Prescribing Information for approved indications, contraindications, warnings and precautions, and adverse events.

Site last updated 02/2026

User Sitemap
Privacy Statement
Health Data Privacy Statement
Conditions of use
California Transparency in Supply Chains

hidden link for autofocus